Shire’s Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation (CIC) in Adults

 Shire’s Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation (CIC) in Adults

Shire’s Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation (CIC) in Adults

Shots:

  • The approval is based on six trials assessing Motegrity vs PBO in 2,484 patients with Chronic Idiopathic Constipation (CIC) in adults
  • P-III study results: normalization of BM frequency (19-38% vs 10-20%); no increase in the risk of MACE events
  • Motegrity (prucalopride) is a qd serotonin-4 receptor agonist (5-HT4) with its expected launch in 2019 in the US

Click here to read full press release/ article | Ref: GlobeNewWire | Image: WSJ

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post